Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effectiveness and Toxicity of Gemcitabine/Lobaplatin Versus Gemcitabine/Cisplatin as Second-line Treatment in Metastatic Breast Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2012 by Harbin Medical University.
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
Qingyuan Zhang, Harbin Medical University
ClinicalTrials.gov Identifier:
NCT01483300
First received: November 25, 2011
Last updated: January 22, 2012
Last verified: January 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: November 2014
  Estimated Primary Completion Date: August 2014 (Final data collection date for primary outcome measure)